Nutraceutical · ChEMBL entry is a mixture-type record (structure_type NONE, molecule_type Unknown, max_phase 2) with no mechanism of action record. Escin is the saponin mixture from Aesculus hippocastanum seed.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Chronic Venous Insufficiency · Varicose Vein · Superficial Thrombophlebitis
Enrolment: 53 · Results not recorded
Coronavirus Infections
Enrolment: 120 · Results not recorded
Impacted Third Molar Extraction · Postoperative Complications
Enrolment: 24 · Results not recorded
Haemorrhoid
Enrolment: 120 · Results not recorded
Postoperative Pain · Facial Swelling · Trismus
Enrolment: 100 · Results not recorded
Postoperative Pain · Oedema · Swelling
Enrolment: 20 · Results not recorded
Anorectal Disorder
Enrolment: 60 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Chronic constriction injury of the sciatic nerve; additional formalin and carrageenan acute inflammatory pain models
Escin widened the thermal threshold, lowered TNF-alpha and IL-1beta, suppressed TLR4/NF-kappaB signalling, reduced GFAP and NGF, and improved viability of LPS-injured PC12 cells.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
